OCS-05 is under clinical development by Oculis and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect OCS-05’s likelihood of approval (LoA) and phase transition for Neuromyelitis Optica (Devic’s Syndrome) took place on 03 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their OCS-05 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

OCS-05 overview

OCS-05 is under development for the treatment of multiple sclerosis, optic neuritis and neuromyelitis optica (Devic’s Syndrome), glaucoma. It is a new chemical entity. It is administered through topical, oral, intravenous and subcutaneous routes. The therapeutic candidate targets intracellular serine/threonine kinase SGK-2. It was also under development for the treatment of glaucoma, amyotrophic lateral sclerosis (ALS), Parkinson disease, Alzheimer's disease (AD), major depressive disorder, diabetic retinopathy and Macular Degeneration.

Oculis overview

Oculis operates as a clinical-stage biopharmaceutical company that offers topical treatments for acute and chronic back as well as front-of-the-eye ophthalmic diseases. Its pipeline product portfolio includes OC-118 a topical treatment for Diabetic Macular Edema; OC-410 for diabetic retinopathy and dry eye; OC-500 for treating wet age-related macular degeneration and retinal vein occlusion. Oculis proprietary solubilizing nanoparticle (SNP) technology platform enables the formulation of a wide range of drugs as non-invasive topical treatments and enhances the bioavailability in the relevant eye tissues. The company has research operations in Reykjavik, Iceland. Oculis is headquartered in Lausanne, Waadt, Switzerland.

Quick View OCS-05 LOA Data

Report Segments
  • Innovator
Drug Name
  • OCS-05
Administration Pathway
  • Intravenous
  • Oral
  • Subcutaneous
  • Topical
Therapeutic Areas
  • Central Nervous System
  • Metabolic Disorders
  • Ophthalmology
Key Developers
  • Sponsor Company: Oculis
  • Originator: Bionure Farma
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.